Top Tweets for #ASHplenary

10 months ago

#ASH25 #ASHPlenary Dr Wei: introducing the plenary #PARADIGM trial! #leusm

1

31

6

10

2K

10 months ago

#ASH25 #ASHPlenary Deciphering the dilemma: Intravenous (IV) iron use in iron deficiency anemia during acute infections 👉🏾 IV iron safe during infection and shown to improve outcome. Dr. Haris Sohail 👏👏 Awesome job!

TalhaBadarMD's tweet photo. #ASH25 #ASHPlenary

Deciphering the dilemma: Intravenous (IV) iron use in iron deficiency anemia during acute infections
👉🏾 IV iron safe during infection and shown to improve outcome.
Dr. Haris Sohail 👏👏 Awesome job! https://t.co/jhiKsFK5Xn

4

96

18

16

5K

10 months ago

#ASH25 #ASHplenary Dr. Lindsley introducing #4 plenary DNA damage response (DDR) mutant clonal hematopoiesis #TP53 #PPM1D #ATM #CHEK2 CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis: conclusion 👇🏽

TalhaBadarMD's tweet photo. #ASH25 #ASHplenary
Dr. Lindsley introducing #4 plenary
DNA damage response (DDR) mutant clonal hematopoiesis #TP53 #PPM1D #ATM #CHEK2

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis: conclusion 👇🏽 https://t.co/IG7aJE6Oh6

10 months ago

#ASH25 #ASHplenary Dr. Lindsley introducing #4 plenary DNA damage response (DDR) mutant clonal hematopoiesis #TP53 #PPM1D #ATM #CHEK2 CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis

0

7

0

2

2K

0

8

2

3

1K

10 months ago

#ASH25 #ASHplenary Dr. Lindsley introducing #4 plenary DNA damage response (DDR) mutant clonal hematopoiesis #TP53 #PPM1D #ATM #CHEK2 CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis

0

7

0

2

2K

10 months ago

#ASH25 #ASHplenary Outcomes of pregnancies in sickle cell patients treated with hydroxyurea : Findings from the escort-HU cohort studies: among 245 pregnancies with SCD. No maternal deaths or malformations noticed.

TalhaBadarMD's tweet photo. #ASH25 #ASHplenary

Outcomes of pregnancies in sickle cell patients treated with hydroxyurea : Findings from the escort-HU cohort studies: among 245 pregnancies with SCD. No maternal deaths or malformations noticed. https://t.co/69MQviotfQ

1

13

5

3

912

almost 3 years ago

@SBenbarche @ASH_hematology @MaxStahlMD @MSKCancerCenter @DrCCutler @aamdsif @ASCO @ASHClinicalNews @ASTCT @IMFmyeloma @End_myeloma @RahulBanerjeeMD @HadidiSamer @MM_Hub @Eddie_Cliff @MyelomaTeacher @Myeloma_Society @MyelomaUK #ASH23 #ASHPlenary 6⃣ REACH trial showed ⬆️Hydroxyurea dose: ⬇️ VOC, acute chest, CVA ⬆️Hb, HbF 💡25-30mg/kg/day=optimized dose 🌟No significant added toxicity ♥️Hope for optimized sickle cell disease Tx in resource-limited settings like sub-Saharan Africa https://t.co/jMwMQ0Ryws

amarkelkar's tweet photo. @SBenbarche @ASH_hematology @MaxStahlMD @MSKCancerCenter @DrCCutler @aamdsif @ASCO @ASHClinicalNews @ASTCT @IMFmyeloma @End_myeloma @RahulBanerjeeMD @HadidiSamer @MM_Hub @Eddie_Cliff @MyelomaTeacher @Myeloma_Society @MyelomaUK #ASH23 #ASHPlenary 6⃣
REACH trial showed ⬆️Hydroxyurea dose:
⬇️ VOC, acute chest, CVA
⬆️Hb, HbF
💡25-30mg/kg/day=optimized dose
🌟No significant added toxicity
♥️Hope for optimized sickle cell disease Tx in resource-limited settings like sub-Saharan Africa
https://t.co/jMwMQ0Ryws https://t.co/mXR5K0rp3a

0

5

1

0

337

almost 3 years ago

@SBenbarche @ASH_hematology @MaxStahlMD @MSKCancerCenter @DrCCutler @aamdsif @ASCO @ASHClinicalNews @ASTCT @IMFmyeloma @End_myeloma @RahulBanerjeeMD @HadidiSamer @MM_Hub @Eddie_Cliff @MyelomaTeacher @Myeloma_Society @MyelomaUK #ASH23 #ASHPlenary 5⃣ Prenatal folate deficiency can program hematopoietic stem cell function during development, impacting self-renewal & engraftment potential in adulthood. 🩸Altered adult gene expression & metabolic profiles 🩸Mitochondrial dysfunction https://t.co/8iSFPer6ye

1

2

1

0

400

almost 3 years ago

@SBenbarche @ASH_hematology @MaxStahlMD @MSKCancerCenter @DrCCutler @aamdsif @ASCO @ASHClinicalNews @ASTCT #ASH23 #ASHPlenary 4⃣ IsKia Ph3 RCT: 1L KRd±Isatuximab in ASCT-eligible Pts with Multiple Myeloma ➕Isa ⬆️ 10^-6 MRD- rates after ASCT (67% vs 48% OR 2.29 p<0.001) ⬆️Heme AEs ❓Clinical significance of MRD- after ASCT (vs PFS/OS) ❓1L IsaKRd vs DRVd https://t.co/V28zS1iryR

amarkelkar's tweet photo. @SBenbarche @ASH_hematology @MaxStahlMD @MSKCancerCenter @DrCCutler @aamdsif @ASCO @ASHClinicalNews @ASTCT #ASH23 #ASHPlenary 4⃣
IsKia Ph3 RCT: 1L KRd±Isatuximab in ASCT-eligible Pts with Multiple Myeloma
➕Isa ⬆️ 10^-6 MRD- rates after ASCT (67% vs 48% OR 2.29 p<0.001)
⬆️Heme AEs
❓Clinical significance of MRD- after ASCT (vs PFS/OS)
❓1L IsaKRd vs DRVd
https://t.co/V28zS1iryR https://t.co/WGarQMip0l

1

5

1

624

almost 3 years ago

#ASH23 #ASHPlenary 2⃣ Small molecule "molecular glue degrader" (dWiz-2) targeted Wiz transcription factor allowing upregulation of HbF. 💡Mouse xenotransplant & macaque studies saw HbF increase to >20% by D28 on Tx 💡Emphasis on global accessibility https://t.co/w3CBYx4pf9

amarkelkar's tweet photo. #ASH23 #ASHPlenary 2⃣
Small molecule "molecular glue degrader" (dWiz-2) targeted Wiz transcription factor allowing upregulation of HbF.
💡Mouse xenotransplant & macaque studies saw HbF increase to >20% by D28 on Tx
💡Emphasis on global accessibility
https://t.co/w3CBYx4pf9 https://t.co/dEm5rTLK8n

1

4

2

0

664

almost 3 years ago

#ASH23 #ASHPlenary 1⃣ AGAVE-201 safety/efficacy study of colony-stimulating factor 1 receptor (CSF-1R) inhibitor Axatilimab for previously Tx chronic GVHD. 💡55% Pt-reported clinically meaningful improvement 💡74% ORR 💡0.3mg/kg Q2W=🌟dose ⬆️FEV1 in some https://t.co/THtX3whQAj

amarkelkar's tweet photo. #ASH23 #ASHPlenary 1⃣
AGAVE-201 safety/efficacy study of colony-stimulating factor 1 receptor (CSF-1R) inhibitor Axatilimab for previously Tx chronic GVHD.
💡55% Pt-reported clinically meaningful improvement
💡74% ORR
💡0.3mg/kg Q2W=🌟dose
⬆️FEV1 in some
https://t.co/THtX3whQAj https://t.co/qUH7N11UEV

2

11

4

3

4K

almost 4 years ago

#ASH22 Outstanding teaching overview slide Dr @beth_psaila as #ASHPlenary introducer for #MPNSM | #JAK2 #CALR #MPL

0

12

1

0

almost 4 years ago

#ASH22 Wow!! Awesome cover story #BreakingMab by Dr Natasha Szuber in yest very important #ASHPlenary well done by Dr @n_gangat & #ASHNewsDaily team !!! @ASH_hematology #ASHKudos 👏🏽

doctorpemm's tweet photo. #ASH22 Wow!! Awesome cover story #BreakingMab by Dr Natasha Szuber in yest very important #ASHPlenary well done by Dr @n_gangat & #ASHNewsDaily team !!! @ASH_hematology #ASHKudos 👏🏽 https://t.co/UsdOGUA2R8

0

28

5

2

0

almost 4 years ago

#ASH22 #MPNSM Dr Reis with a major discovery at #ASHPlenary final talk of session. Super important discovery in MPN field. Phase I study planned for 2023 !! @ASH_hematology

doctorpemm's tweet photo. #ASH22 #MPNSM Dr Reis with a major discovery at #ASHPlenary final talk of session. Super important discovery in MPN field. Phase I study planned for 2023 !! @ASH_hematology https://t.co/KXnw8OJbQw

0

9

3

0

almost 4 years ago

#ASH22 | #ASHPlenary Dr Reis Notable talk. Major discovery. First #CALR-mutant specific #mAb !!!!!@ASH_hematology

1

34

6

1

0

almost 4 years ago

#ASH22 #ASHPlenary Wow !!! Discovery of a #CALR mutant specific #mAb for #MPNSM !!!! 👏🏽 @beth_psaila @ASH_hematology

1

49

11

2

0

almost 4 years ago

#ASH22 WOW !! Standing room only #ASHPlenary ! @ASH_hematology | #lymsm #leusm #MPNSM

1

40

3

0

almost 4 years ago

#ASH22 #MPNSM Very much looking forward to this super important abstract in our MPN field soon at #ASHPlenary session !!! #CALR | cc: @mpndoc @KuykendallMd @bose_prithviraj @MDmasarova @LindaResar @KMirza @juliamaxson @NitinJainMD #leusm #MPNSM @ASH_hematology

doctorpemm's tweet photo. #ASH22 #MPNSM Very much looking forward to this super important abstract in our MPN field soon at #ASHPlenary session !!! #CALR | cc: @mpndoc @KuykendallMd @bose_prithviraj @MDmasarova @LindaResar @KMirza @juliamaxson @NitinJainMD #leusm #MPNSM @ASH_hematology https://t.co/74FiSL6o8w

0

14

0